Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Health‐related quality of life ‐ all trials Higher scores indicate improved health‐related quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin probably leads to lower hepatic encephalopathy ‐ total number compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Blood ammonia measured in μg/mL at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Number Connection Test A, assessed using: seconds (1 trial) or Z‐score (1 trial) at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Time to resolution of acute illness · children with acute pneumonia
1 finding from 1 review
Number of days in hospital (duration of hospitalisation) · children with acute pneumonia
1 finding from 1 review
Mortality rate ( · children with acute pneumonia
Vitamin D showed no clear difference in mortality rate ( compared with placebo (low certainty).
1 finding from 1 review
Cardiac T2* value · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
MIC · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
LVEF (echocardiography) · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
Ferritin (µg/L) · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
Liver T2* value · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
LIC · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
Adverse events · or population: people with transfusion‐dependent beta thalassaemia
1 finding from 1 review
Irritability · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐injury · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Adverse effects · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
It is very uncertain whether attention deficit hyperactivity disorder (ADHD)‐related drugs changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review